Obesity increases the risks of diabetes, hypertension, and cardiovascular diseases, ultimately contributing to mortality. Korean Society for the Study of Obesity (KSSO) was established to improve the management of obesity through research and education; to that end, the Committee of Clinical Practice Guidelines of KSSO reviews systemic evidence using expert panels to develop clinical guidelines. The clinical practice guidelines for obesity were revised in 2018 using National Health Insurance Service Health checkup data from 2006 to 2015. Following these guidelines, we added a category, class III obesity, which includes individuals with body mass index (BMI) ≥35 kg/m 2 . Agreeing with the International Federation for the Surgery of Obesity and Metabolic Disorders, Asian Pacific Chapter consensus, we determined that bariatric surgery is indicated for Korean patients with BMI ≥35 kg/m 2 and for Korean patients with BMI ≥30 kg/m 2 who have comorbidities. The new guidelines focus on guiding clinicians and patients to manage obesity more effectively. Our recommendations and treatment algorithms can serve as a guide for the evaluation, prevention, and management of overweight and obesity.
INTRODUCTION
The prevalences of obesity and associated disease are rapidly increasing among Korean adults. 1 Many health problems are associated with obesity and excessive fat. 2 Obesity is associated with increased risks for type 2 diabetes mellitus (T2DM), hypertension (HTN), dyslipidemia, metabolic syndrome, coronary heart disease, other atherosclerotic diseases, and non-alcoholic fatty liver disease. for each topic using expert panels to produce the latest guidelines.
The new revised guidelines summarize evidence-based recommendations and treatment guidelines, including the definition of obesity, behavioral therapy, and surgical therapy. In this article, we discuss the 2018 KSSO guidelines for the management of overweight and obesity in adults. 
OBESITY PREVALENCE TRENDS BY SEX, AGE, AND THREE COMORBIDITIES, BASED ON THE PRESENCE OF ABDOMINAL OBESITY

DIAGNOSIS OF OBESITY
In clinical practice, body fat is measured using BMI. 2 Lower BMI cutoff points apply to other populations, including East Asians. 6 East Asians generally have higher body fat percentages than non-Asians at the same BMI. 7 Therefore, the cutoff values for defining overweight and obesity are lower for East Asians than for non-Asians according to the World Health Organization (WHO). 8 Deurenberg et al. 9 reported that at the same BMI, body fat percentages in Asians population were 3%-5% higher than in subjects of European descent, suggesting that the relationship between BMI and percentage body fat is different in Asians than in non-Asians.
Oh et al. 10 
DETERMINING WEIGHT LOSS AND HEALTH GOALS
Maintaining a 3% to 5% weight loss can significantly reduce the risk of cardiovascular disease or diabetes. Therefore, we recommend a 5% to 10% weight loss within 6 months of diagnosis. In general, patients experiencing lifestyle modifications achieve maximum weight loss within 6 months of initiation. Their weight then becomes constant, and they typically regain weight over time. This increase in body weight also occurs during the use of medication although weight regain can be slowed with continued medication use. 13 Patients undergoing bariatric surgery might be able to maintain weight for longer periods of time.
14 Thus, patients should be advised to adhere to lifestyle (dietary and exercise) modifications for more than 1 year for successful maintenance of weight loss.
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TREATMENT OF OBESITY
Below, we discuss a three-part treatment strategy including lifestyle interventions, pharmacotherapy, and bariatric surgery according to the KSSO recommendations. Lifestyle interventions such as diet, physical activity, and behavior therapy are the first line of treatment for patients with obesity. 5 Drug and surgical treatments are therapeutic options if you fail to get a first line of treatment with obesity.
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LIFESTYLE INTERVENTIONS
Cognitive behavior therapy can change patient beliefs and understanding about weight regulation. 5 The KSSO behavior modification guidelines include dietary and exercise modifications. 4 to all participants who hope to lose weight. 13 Weight loss requires the maintenance of a total energy deficit through caloric restriction and physical activity. 13 Energy intake reductions of over 500 kcal/day can usually be achieved with a total daily intake of 1,200 to 1,500 kcal/day in female and 1,500 to 1,800 kcal/day in male. 13 Various dietary approaches including low calorie diet, macronutrients modified diets and so on can be used to treat obesity based on individual characteristics. However, these approaches should be nutritionally adequate and create energy deficit. 13 Physical activity is necessary for weight loss and weight maintenance. At the start, more than moderate physical activity is recom- Thus, the 2018 KSSO guidelines advise obese patients to pursue lifestyle changes such as food intake reductions and increased physical activity when attempting weight loss. It is recommended that behavior therapy be continued for at least 6 months to effectively lose weight and for at least 1 year to maintain weight loss.
Before treatment of obesity, the patient needs to be evaluated to determine whether they are ready to lose weight, and the treatment goals should be agreed upon between the physician and the patient according to the individual's health condition. The primary goal of weight loss should be to reduce body weight by 5% to 10% within 6 months, but losses of only 3%-5% of body weight can improve cardiovascular risk factors.
To determine whether exercise is to be performed and to evaluate exercise capacity, the KSSO guidelines recommend that patients check their health before exercise. It is recommended that exercise regimens include recommendations regarding type, intensity, time, and frequency of exercise.
PHARMACOLOGIC INTERVENTIONS
The Asia-Pacific WHO recommendations suggest that the pharmacotherapy of obesity should be considered when BMI is ≥ 25 kg/m 2 , or ≥ 23 kg/m 2 with associated comorbidities. 8 The KSSO recommends that pharmacotherapy for obesity should be considered when intensive life style modifications fail to result in weight loss in obese 
BARIATRIC SURGERY
Recent clinical studies suggest that bariatric surgery is a most effective treatment for morbidly obese patients and that it decreases the risks of obesity-related diseases and health-related costs. 16 In after surgery is about 45% to 90%. 17, 18 Hyperlipidemia is improved at rates of 70% or more and HTN is improved at rates of about 61%. 17 The degree of weight loss after surgery depends on the surgical procedure performed. 16 According to a meta-analysis, the mean average weight loss among bariatric surgery patients was 61.2% (95% CI, 58.1%-64.4%).
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According to the Committee of Korean Society for Metabolic and Bariatric Surgery, 1,687 bariatric procedures were performed at 29 institutions based on a nationwide survey. 19 The most frequently performed surgery was adjustable gastric banding (71.8%), performed after sleeve gastrectomy (14.0%). 19 The researchers emphasized that treatment outcomes significantly depended on, among other factors, patient compliance with long-term follow-up. 16 The 2018 KSSO guidelines for the management of obesity include the following recommendations regarding bariatric surgery. 
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